To further evaluate ALK expression in metastatic prostate cancer, we first performed in silico analyses of previously published RNA-sequencing data of the University of Washington (UW) rapid autopsy cohort (Fig. 3A) and the Stand Up2 Cancer (SU2C) international dream team cohort (Fig. 3B; refs. 13, 32, 33). Here, ALK is linked to metastatic prostate carcinoma.